DOCSLIB.ORG

Pipeline Progress

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Pipeline Progress Second quarter results 2020 Audiocast presentation 16 July 2020 2 Forward looking statements This presentation contains forward-looking statements that provide our expectations or forecasts of future events such as new product developments and regulatory approvals and financial performance. Camurus is providing the following cautionary statement. Such forward-looking statements are subject to risks, uncertainties and inaccurate assumptions. This may cause actual results to differ materially from expectations and it may cause any or all of our forward-looking statements here or in other publications to be wrong. Factors that may affect future results include currency exchange rate fluctuations, delay or failure of development projects, loss or expiry of patents, production problems, unexpected contract, patent, breaches or terminations, government-mandated or market-driven price decreases, introduction of competing products, Camurus‘ ability to successfully market products, exposure to product liability claims and other lawsuits, changes in reimbursement rules and governmental laws and interpretation thereof, and unexpected cost increases. Camurus undertakes no obligation to update forward-looking statements 3 Agenda • Second quarter 2020 overview Company participants • Buvidal progress in EU & Australia Fredrik Tiberg, PhD President & CEO, Head R&D • Pipeline update • Key take-aways Eva Pinotti Lindqvist • Revised Outlook 2020 Chief Financial Officer • Q&A Richard Jameson Chief Commercial Officer 4 Continued strong performance in the second quarter 2020 • Continued strong Buvidal sales growth and expansion to second-wave markets • Full-year 2020 net revenue guidance raised • Request for final approval of Brixadi™ submitted to, and accepted by, the US FDA • Arbitration process initiated in England • Recruitment in CAM2029 Phase 3 studies reinitiated after Covid-19 stall • Positive Phase 2 data for Rhythm’s once- weekly drug candidate for obesity disorders o MSEK 300 raised in directed share issue 5 Financial overview second quarter 2020 Key figures Product sales by quarter MSEK Q2 2020 (Q2 2019) H1 2020 (H1 2019) MSEK Apr-Jun Δ Jan-Jun Δ 80 75.8 Total revenues 80.9 (11.9) +579% 130.2 (30.4) +328% 70 +56% whereof product sales 75.8 (11.3) +568% 124.4 (22.3) +458% 60 OPEX 102.1 (120.1) -15% 219.4 (219.5) 0% 50 48.6 40 Operating result -23.3 (-109.8) +79% -100.3 (-194.2) +48% +60% 30 30.3 Result for the period -20.0 (-87.6) +77% -81.5 (-155.3) +48% +55% 20 19.5 Result per share, before 11.0 11.3 +73% and after dilution, SEK -0.39 (-1.70) +77% -1.58 (-3.32) +53% 10 Cash position 222.0 (283.1) -22% 222.0 (283.1) -22% 0 Q1 Q2 Q3 Q4 Q1 Q2 2019 2020 6 Opioid dependence – escalating global health crisis • Largest society burden of all drugs1 Covid-19 causing spike in US opioid overdoses • 58 million opioid users worldwide1 +42% • High need for better access to care and new treatment alternatives +29% • Investment in treatment brings substantial +18% value and saves lives +16% • Significant limitation with current daily medications -0.3% ‒ Diversion, misuse, overdosing, poor retention, burdens and stigma of daily buprenorphine and Jan Feb Mar Apr May methadone medications Increase of US suspected overdoses per month during 2020 compared to the same month in 20192 1. United Nations: World drug report 2020; 2. Washington Post https://www.washingtonpost.com/health/2020/07/01/coronavirus-drug- overdose/ and ODMAP 7 Buvidal® – flexible long-acting treatment of opioid dependence Flexible-dose, weekly and monthly, subcutaneous buprenorphine for treatment of opioid dependence within a framework of medical, social and psychological treatment in adults and adolescents 16 years or over1 Source: 1Buvidal Summary of Product Characteristics (SmPC), 2018 8 Continued strong growth of Buvidal •Increasing market share Buvidal sales increased by >50% for the fourth consecutive quarter Approx. 9,500 patients in treatment with Buvidal Covid-19 highlights advantages of long-acting treatment • Catalyst for transition from daily to depot treatment in both outpatient and criminal justice settings, but also limits access to HCPs •Improved market access Reimbursement approved by Swedish TLV Expanded prescriber base in Australia Physician remuneration system changed in Germany •Expansion in second-wave markets initiated Buvidal launched in Austria in May 2020 Belgium, Netherlands, Iceland and Spain next on track Patients in early access programs in MENA region * Measured by product sales 9 Regulatory progress with Buvidal® (Brixadi™) •Camurus’ regulatory submissions •Braeburn preparing for US launch Market authorization applications Clear path to final market approval, under review in New Zealand and after FDA granting Citizen Petition in Switzerland Nov. 2019 Line-extension application for label Request for final FDA approval of the enhancements submitted to EMA NDA for Brixadi accepted by FDA with PDUFA date 1 Dec. 2020 •Availability of Buvidal in MENA All product requirements in place for a final approval Market authorization application by FDA final approval of Brixadi Medison under review in Israel expected 1 Dec 2020 – triggering a Early access programs and regulatory $35 million milestone payment to filings initiated with collaboration Camurus partner NewBridge Pharmaceuticals 1. Camurus’ press release 15 June 2020 https://mb.cision.com/Main/13456/3134723/1264520.pdf 10 Growing scientific evidence base for Buvidal Important publications1-6 Presentations at Scientific Conferences in 2020 2020 Q1 Q2 Q3 Q4 International ASAM CPDD AAAP Conferences 2-5 Apr 10-13 Dec Virtual 20-24 Jun San Antonio, USA Virtual ISAM 13-16 Nov Victoria, Canada European IOTOD Nord Op Sym 24-25 Sept 1-2 Oct Conferences Virtual Uppsala, Sweden ALBATROS 27-29 Oct Paris, France National RCGP MDAP SFA Odensee Kon SIPaD RCGP H&J 30-31 Jan 12-13 Mar 6-7 Nov 11-13 Nov 25-26 Nov Conferences London, UK Paris, France Grundlsee, Aut Sorrento, Italy Newcastle, UK Encephale Fin S Add Med SSA SEPD S Esp San Pen 22-24 Jan 5-6 Mar 5-6 Nov 15-17 Nov 19-21 Nov Paris, France Helsinki, Finland Newcastle, UK Seville, Spain Madrid, Spain DGS konf Feder SerD J Sociodrog 30 Oct – 1 Nov 18-20 Nov 2-4 Dec 1Chappuy et al,Therapie. 2020 May 18:S0040-5957(20)30096-2; 2Hjelmström Berlin, Germany Rome, Italy Madrid, Spain et al, Drug Dev Ind Pharm 2020;46(1):1-7; 3Frost et al, Addiction, 2019;114(8):1416-1426, 4Lofwall et al. JAMA Int. Med. 2018;178(6); 764-773; 5Walsh et al, JAMA Psychiatry 2017;74(9):894-902; 6Albayaty et al, Adv Ther. 2017 34(2):560-575; 11 Compelling clinical evidence from head-to-head DEBUT study presented at CPDD •DEBUT – Depot Evaluation Buprenorphine Study met primary endpoint demonstrating superiority Utilization Trial for TSQM global satisfaction1 Difference ‒ Randomized, multi-site, open-label, active-controlled study Scheduled Visit Statistic Buvidal SL BPN SOC† p-value of Buvidal vs standard of care in 120 adult outpatients with (Buvidal - SL BPN) opioid dependence to compare patient reported outcomes Baseline (Mean) 71.2 73.8 - - (PROs) Week 24 (LS Mean) 82.5 74.3 8.2 0.0143 ‒ Primary endpoint: patient reported TSQM† global satisfaction score Treatment period (LS Mean) 82.4 73.8 8.6 0.0016 ‒ Secondary endpoints (selected): other treatment satisfaction domains, treatment burden, quality of life, Primary endpoint First secondary endpoints opioid related behaviors and general health outcomes Global satisfaction Convenience Effectiveness Side Effects score Score Score Score 100 Buvidal Weekly & Monthly CAM2038Buvidal flexible dosing 90 SL BPN * * * * * 80 * Screening R Follow-up period 70 60 n=120 BPN SoC 50 flexible dosing Mean TSQM score 40 w0 w12 w24 w0 w12 w24 w0 w12 w24 w0 w12 w24 Day -28 to -1 Day 1 Week 24 Week 26 1. Lintzeris N, Dunlop A, Haber P, Lubman D, Graham R, Hutchinson S, Hjelmstrom P, Svedberg A, Peterson S, Tiberg F. Results of the DEBUT Study – A Multisite, Open-Label RCT of Weekly and Monthly Depot Buprenorphine Injections (CAM2038) Vs. Daily Sublingual Therapy Investigating Patient Reported Outcomes in Treatment of Opioid Use Disorder. Presented at The College on Problems of Drug Dependence, (CPDD) Virtual Meeting June 22-24, 2020. † Statistically significant p-value ≤ 0.05 TSQM – Treatment satisfaction questionnaire for medication ; SL – sublingual; BPN – buprenorphine; SOC – Standard of Care 12 Buvidal highly cost-effective in the UNLOCT-T study – further studies under way •UNLOC-T – Safety and feasibility of depot •ARIDE – Addiction recovery among opioid- buprenorphine in NSW custodial settings dependent patients treated with injectable ‒ Prospective, non-randomized, open-label, multicenter study in subcutaneous depot buprenorphine 129 OUD patients treated with Buvidal or methadone in 8 prisons ‒ Non-randomized prospective non-interventional 1 observational study with control group design •Results (treatment-as-usual, TAU) performed in Germany The safety profile pf Buvidal was satisfactory with most AEs ‒ ‒ The primary objective is to evaluate quality of life. being mild in severity and no severe treatment related AEs Secondary objectives include satisfaction, illicit ‒ Treatment retention was high (81% at week 16) substance use, social participation and cost- ‒ Treatment costs with Buvidal was ~1/3 of daily methadone and effectiveness. ~1/10 of daily sublingual buprenorphine ‒ Patient recruitment started in March 2020 ‒ Following the study treatment with depot BPN in NSW prisons have expanded rapidly and now include over 640 patients Buvidal
Load more

Recommended publications
  • CAM2038 Weekly Opioid Dependence
    Cowen & Co. Annual Health Care Conference 2017 Camurus Advancing late stage pipeline with high market potential Company Presentation, 7 March 2017 Forward-looking statements This presentation contains forward-looking statements that provide our expectations or forecasts of future events such as new product developments and regulatory approvals and financial performance. Camurus is providing the following cautionary statement. Such forward-looking statements are subject to risks, uncertainties and inaccurate assumptions. This may cause actual results to differ materially from expectations and it may cause any or all of our forward-looking statements here or in other publications to be wrong. Factors that may affect future results include currency exchange rate fluctuations, delay or failure of development projects, loss or expiry of patents, production problems, unexpected contract, patent, breaches or terminations, government-mandated or market-driven price decreases, introduction of competing products, Camurus‘ ability to successfully market products, exposure to product liability claims and other lawsuits, changes in reimbursement rules and governmental laws and interpretation thereof, and unexpected cost increases. Camurus undertakes no obligation to update forward-looking statements 2 Camurus overview LISTED ON NASDAQ STOCKHOLM • Innovation that delivers 3rd DEC, 2015 − Proprietary FluidCrystal® technology used in 10 clinical programs − Preclinical to NDA/MAA enabling MARKET CAP pipeline programs − Expansive and rewarding pharma partnerships
    [Show full text]
  • Camurus Company Presentation
    Corporate presentation Updated 15 July 2021 2 Forward looking statements This presentation contains forward-looking statements that provide our expectations or forecasts of future events such as new product developments and regulatory approvals and financial performance. Camurus is providing the following cautionary statement. Such forward-looking statements are subject to risks, uncertainties and inaccurate assumptions. This may cause actual results to differ materially from expectations and it may cause any or all of our forward-looking statements here or in other publications to be wrong. Factors that may affect future results include currency exchange rate fluctuations, delay or failure of development projects, loss or expiry of patents, production problems, unexpected contract, patent, breaches or terminations, government-mandated or market-driven price decreases, introduction of competing products, Camurus‘ ability to successfully market products, exposure to product liability claims and other lawsuits, changes in reimbursement rules and governmental laws and interpretation thereof, and unexpected cost increases. Camurus undertakes no obligation to update forward-looking statements 3 Long-acting medications addressing key healthcare challenges 4 Camurus snapshot Rapidly growing commercial Broad late-stage pipeline stage company • +10 innovative clinical programs in addiction, • Fully operational infrastructure in Europe pain, endocrine disorders and oncology and Australia • Three Phase 3 programs • Buvidal® to date available in
    [Show full text]
  • Company Presentation
    Company presentation November 2020 2 Forward looking statements This presentation contains forward-looking statements that provide our expectations or forecasts of future events such as new product developments and regulatory approvals and financial performance. Camurus is providing the following cautionary statement. Such forward-looking statements are subject to risks, uncertainties and inaccurate assumptions. This may cause actual results to differ materially from expectations and it may cause any or all of our forward-looking statements here or in other publications to be wrong. Factors that may affect future results include currency exchange rate fluctuations, delay or failure of development projects, loss or expiry of patents, production problems, unexpected contract, patent, breaches or terminations, government-mandated or market-driven price decreases, introduction of competing products, Camurus‘ ability to successfully market products, exposure to product liability claims and other lawsuits, changes in reimbursement rules and governmental laws and interpretation thereof, and unexpected cost increases. Camurus undertakes no obligation to update forward-looking statements Long-acting medications addressing key healthcare challenges 4 Corporate highlights Rapidly growing commercial Broad late-stage pipeline stage company • +10 innovative clinical programs in • Fully operational infrastructure in Europe addiction, pain, oncology, endocrine and Australia disorders and CV diseases • Buvidal® to date launched in 9 countries • Two ongoing
    [Show full text]
  • Camurus Company Presentation Cowen 2020
    Company Presentation Cowen & Co. 40th Annual Health Care Conference 2 March 2020, Boston, MA Forward looking statements This presentation contains forward-looking statements that provide our expectations or forecasts of future events such as new product developments and regulatory approvals and financial performance. Camurus is providing the following cautionary statement. Such forward-looking statements are subject to risks, uncertainties and inaccurate assumptions. This may cause actual results to differ materially from expectations and it may cause any or all of our forward-looking statements here or in other publications to be wrong. Factors that may affect future results include currency exchange rate fluctuations, delay or failure of development projects, loss or expiry of patents, production problems, unexpected contract, patent, breaches or terminations, government-mandated or market-driven price decreases, introduction of competing products, Camurus‘ ability to successfully market products, exposure to product liability claims and other lawsuits, changes in reimbursement rules and governmental laws and interpretation thereof, and unexpected cost increases. Camurus undertakes no obligation to update forward-looking statements 2 LISTED ON NASDAQ STO; TICKER CAMX MARKET CAP Camurus in brief ~ SEK 4.5 billion EMPLOYEES: 130 HQ: Lund, Sweden REG. OFFICES: Cambridge, Mannheim, Sydney, Paris ® Unique FluidCrystal Two Phase 3 programs nanotechnologies • Late-stage pipeline with 10 innovative • In-house developed with strong IP clinical
    [Show full text]
  • Invitation to Subscribe for Shares in Camurus AB
    Invitation to subscribe for shares in Camurus AB Please note that the subscription rights are expected to have an economic value. In order to not lose the value of the subscription rights, holders must either: • Exercise the subscription rights received and subscribe for new shares no later than 25 March 2019, or • Sell the subscription rights received, but not exercised, no later than 21 March 2019. Please note that shareholders with nominee-registered shareholdings subscribe for new shares through their custodian/nominee. The distribution of this prospectus and the subscription for new shares are subject to restrictions in certain jurisdictions (see “Selling and transfer restrictions”). FINANCIAL ADVISORS IMPORTANT INFORMATION For certain definitions used in this prospectus, see “Certain definitions” on the next page. A Swedish version of this prospectus has been approved and registered by the Swedish Financial Supervisory Authority (the “SFSA”) in accordance with Chapter 2, sections 25 and 26 of the Swedish Financial Instruments Trading Act (lagen (1991:980) om handel med finansiella instrument). Approval and registration does not imply that the SFSA guarantees that the information in the prospectus is accurate or complete. The prospectus and the offering hereunder are governed by Swedish law. Disputes arising in connection with this prospectus, the offering and related legal matters shall be settled exclusively by Swedish courts. The prospectus has been prepared in both Swedish and English language versions. In the event of any conflict between the versions, the Swedish version shall prevail. Camurus has not taken, and will not take any actions to allow a public offering in any jurisdiction other than Sweden.
    [Show full text]
  • Camurus Had an Excellent Start of 2021 with Strong Revenue Growth, New Regulatory Approvals and Progress in the Pipeline”
    INTERIM REPORT FOR THE FIRST QUARTER 2021 “Camurus had an excellent start of 2021 with strong revenue growth, new regulatory approvals and progress in the pipeline” Camurus is an international science-led biopharmaceutical company committed to developing and commercializing innovative medicines for the treatment of severe and chronic conditions. New drug products with best-in-class potential are conceived based on the unique proprietary FluidCrystal® drug delivery technologies and its extensive R&D and sales expertise. Camurus’ clinical pipeline includes product candidates for the treatment of cancer, endocrine diseases, pain and addiction, which are developed in-house and in collaboration with international pharmaceutical companies. Camurus’ share is listed on Nasdaq Stockholm under the ticker CAMX. For more information, visit camurus.com First quarter summary Q1 • Total revenue amounted to SEK 126 (49) million, an increase of 155% (161% at CER1) • Product sales were SEK 124 (49) million, an increase of 156% (162% at CER) • Sales growth was 20% (18% at CER) compared to the previous quarter Total revenue • Market approval for Buvidal in New Zealand SEK 126 million • CHMP recommended approval of a new 160mg dose of Buvidal in the EU +155% • Buvidal launched in Spain and the first hundred patients received treatment • Positive decision from health economic evaluation of Buvidal by Haute Autorité de Santé in France Product sales • FDA issued Safe to Proceed letter for the start of a Phase 3 study of CAM2029 for the treatment of SEK 124 million neuroendocrine tumors +156% • Scientific advice with FDA regarding the clinical program for CAM2029 for polycystic liver disease • New patent issued for CAM2038 Weekly in the US with patent term until July 2032 Operating result • The financial outlook for 2021 is unchanged; total revenue SEK 680 – 750 million2, SEK -26 million whereof product sales SEK 620 – 680 million, and the operating result SEK -120 – 0 million2 +66% 1) At constant exchange rates in January 2021.
    [Show full text]
  • Solasia Acquires Exclusive License and Distribution Rights from Camurus for Episil® Oral Liquid in Japan and China
    Camurus AB Press release Ideon Science Park SE-223 70 Lund, Sweden www.camurus.com Phone: +46 46 286 57 30 Solasia acquires exclusive license and distribution rights from Camurus for episil® oral liquid in Japan and China Lund, Sweden, and Tokyo, Japan — March 30, 2015 — Camurus AB (“Camurus”) and Solasia Pharma K.K. (“Solasia”) jointly announced today that they have entered into a license and distribution agreement for episil® oral liquid, a unique and effective treatment for the pain of oral mucositis, a treatment-limiting side effect of some cancer therapies, as well as other oral lesions. As part of the agreement Solasia receives exclusive commercialization rights to episil® in Japan and China, where it has ongoing operations and is building a specialty pharmaceutical infrastructure in the area of oncology and cancer supportive care. Solasia plans to first launch episil® in China followed by Japan. “We are pleased to enter into this collaboration with Camurus, and for the opportunity to commercialize episil® in Japan and China” said Yoshihiro Arai, President and Representative Director of Solasia. “Solasia specializes in innovative oncology treatments, and episil® will take its place as one of the core products in our oncology pipeline”, he continued, noting that episil® fills an important unmet need in daily pain management associated with cancer care, and will contribute to improved quality of life for cancer patients in Japan and China. “The new partnership with Solasia expands Camurus’ distributor network for episil® oral liquid in two of the key markets in Asia”, said Fredrik Tiberg, President and CEO of Camurus.
    [Show full text]
  • Fourth Quarter & Full Year Results 2019
    Fourth quarter & full year results 2019 12 February 2020 Forward looking statements This presentation contains forward-looking statements that provide our expectations or forecasts of future events such as new product developments and regulatory approvals and financial performance. Camurus is providing the following cautionary statement. Such forward-looking statements are subject to risks, uncertainties and inaccurate assumptions. This may cause actual results to differ materially from expectations and it may cause any or all of our forward-looking statements here or in other publications to be wrong. Factors that may affect future results include currency exchange rate fluctuations, delay or failure of development projects, loss or expiry of patents, production problems, unexpected contract, patent, breaches or terminations, government-mandated or market-driven price decreases, introduction of competing products, Camurus‘ ability to successfully market products, exposure to product liability claims and other lawsuits, changes in reimbursement rules and governmental laws and interpretation thereof, and unexpected cost increases. Camurus undertakes no obligation to update forward-looking statements 2 Agenda • Fourth quarter 2019 overview Participants • Buvidal progress in EU & Australia Fredrik Tiberg, PhD • US approval and launch status President & CEO, Head R&D • R&D pipeline update • Key take-aways Eva Pinotti Lindqvist Chief Financial Officer • Q&A 3 Financial overview Financials Q4 2019 FY 2019 2019 Product sales 2020 Guidance FY 2020 MSEK MSEK MSEK 80 72.1 *) Net revenue 35.0 (7.8) 105.6 (49.3) 70 Total revenues 290 – 330 60 – product sales 240 – 280 – product sales 30.3 (5.1) 72.1 (11.3) 50 41.9 OPEX 570 – 610 Operating 40 result -88.4 (-103.2) -360.0 (-287.2) MSEK *) 30 excl.
    [Show full text]
  • Brixadi™In the US
    Company presentation July 2020 2 Forward looking statements This presentation contains forward-looking statements that provide our expectations or forecasts of future events such as new product developments and regulatory approvals and financial performance. Camurus is providing the following cautionary statement. Such forward-looking statements are subject to risks, uncertainties and inaccurate assumptions. This may cause actual results to differ materially from expectations and it may cause any or all of our forward-looking statements here or in other publications to be wrong. Factors that may affect future results include currency exchange rate fluctuations, delay or failure of development projects, loss or expiry of patents, production problems, unexpected contract, patent, breaches or terminations, government-mandated or market-driven price decreases, introduction of competing products, Camurus‘ ability to successfully market products, exposure to product liability claims and other lawsuits, changes in reimbursement rules and governmental laws and interpretation thereof, and unexpected cost increases. Camurus undertakes no obligation to update forward-looking statements Long-acting medications addressing key healthcare challenges 4 Corporate highlights Rapidly growing commercial Broad late-stage pipeline stage company • 10 innovative clinical programs in • Fully operational commercial addiction, pain, oncology, endocrine infrastructure in Europe and Australia disorders and CV diseases • Buvidal® to date launched in 8 countries • Two
    [Show full text]
  • Covid-19 Causing Spike in Opioid Overdoses
    Company presentation November 2020 2 Forward looking statements This presentation contains forward-looking statements that provide our expectations or forecasts of future events such as new product developments and regulatory approvals and financial performance. Camurus is providing the following cautionary statement. Such forward-looking statements are subject to risks, uncertainties and inaccurate assumptions. This may cause actual results to differ materially from expectations and it may cause any or all of our forward-looking statements here or in other publications to be wrong. Factors that may affect future results include currency exchange rate fluctuations, delay or failure of development projects, loss or expiry of patents, production problems, unexpected contract, patent, breaches or terminations, government-mandated or market-driven price decreases, introduction of competing products, Camurus‘ ability to successfully market products, exposure to product liability claims and other lawsuits, changes in reimbursement rules and governmental laws and interpretation thereof, and unexpected cost increases. Camurus undertakes no obligation to update forward-looking statements Long-acting medications addressing key healthcare challenges 4 Corporate highlights Rapidly growing commercial Broad late-stage pipeline stage company • +10 innovative clinical programs in • Fully operational infrastructure in Europe addiction, pain, oncology, endocrine and Australia disorders and CV diseases • Buvidal® to date launched in 10 countries • Two ongoing
    [Show full text]
  • Annual Report 2015 Contents This Is Camurus
    INNOVATIVE NANOSCALE THERAPEUTICS ANNUAL REPORT 2015 CONTENTS THIS IS CAMURUS This is Camurus ................................................................................................ 1 Leading innovation Key performance indicators ............................................................. 2 • FluidCrystal® – award-winning drug delivery technology 2015 In brief ......................................................................................................... 3 • Broad and advanced product pipeline Statement from the CEO ...................................................................... 4 • More than 400 patents and patent applications Operating environment........................................................................ 6 Strategy..................................................................................................................... 7 The patient in focus Technology platforms ..........................................................................10 • Simple and flexible administration Our development portfolio ..........................................................14 • Long-acting formulations for improved compliance Marketing organisation ......................................................................18 • Improved treatment outcomes and quality of life Employee portraits ..................................................................................20 Our development portfolio, cont. .........................................21 Strategic partnerships Early R&D projects ....................................................................................26
    [Show full text]
  • 2018 Otte, Liquid Crystalline Drug Delivery Vehicles for Oral and IV
    International Journal of Pharmaceutics 539 (2018) 175–183 Contents lists available at ScienceDirect International Journal of Pharmaceutics journal homepage: www.elsevier.com/locate/ijpharm Liquid crystalline drug delivery vehicles for oral and IV/subcutaneous T administration of poorly soluble (and soluble) drugs ⁎ Andrew Ottea, , Bong-Kwan Sohb, Gwangheum Yoonb, Kinam Parka,c a Purdue University, Weldon School of Biomedical Engineering, West Lafayette, IN 47907, USA b Chong Kun Dang Research Institute, 315-20, Dongbaekjukjeondaero, Giheung-gu, Youngin-si, Gyeonggi-do 16995, South Korea c Purdue University, Department of Industrial and Physical Pharmacy, West Lafayette, IN 47907, USA ARTICLE INFO ABSTRACT Keywords: Poorly soluble drug molecules often have low bioavailability issues and absorption problems in the clinical Liquid crystal setting. As the number of poorly soluble drugs increases from discovery, developing technologies to enhance Drug delivery their solubility, while also controlling their release is one of the many challenges facing the pharmaceutical Cubosome industry today. Liquid crystalline systems, nanoparticulate or macro-matrix, self-assemble in the presence of an Hexosome aqueous environment and can provide a solubility enhancement, while also controlling the drug release rate. Poorly soluble drug This review examines the fundamentals of liquid crystalline systems through the representative literature, concluding with examples of liquid crystalline systems in clinical trials development. The review focus is on the potential of utilizing liquid crystalline systems for poorly soluble drugs, in the areas of oral delivery and IV/ subcutaneous, followed by water soluble molecules. Key considerations in utilizing liquid crystalline systems advantages while also discussing potential areas of key research that may be needed will be highlighted.
    [Show full text]